# Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.

> PubMed lists PMID 42388932 in Cureus as Published Erratum, Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42388932-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42388932-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42388932-tirzepatide-v1.json
- Content SHA-256: `9149ec77f32c92770666e1123fb0ef611cd3b3b31d49520527c8ca7f1d50498f`

## Claims and source pins

### Headline

Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review. ([`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`](#source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522))

### Summary

PubMed lists PMID 42388932 in Cureus as Published Erratum, Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`](#source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522))

### Paragraph 1

PubMed lists PMID 42388932 in Cureus as Published Erratum, Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`](#source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`](#source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522))

## Sources

<a id="source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522"></a>
- **Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review. · retained source version 1:2026-07-06:current:5f567d3e452268241bfe8b38e9cb67d478ecfc199e088ed494e40b8723452f3b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42388932/) (`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42388932-tirzepatide-v1.json SHA-256: 9149ec77f32c92770666e1123fb0ef611cd3b3b31d49520527c8ca7f1d50498f.